00:38 , Aug 16, 2019 |  BC Innovations  |  Emerging Company Profile

Grace: seeking cures in pathological roots

Grace Science is targeting the root of a recently discovered genetic disorder for not just the ultra-rare condition but also for common diseases including cancer. Grace Science LLC’s origins stem from the diagnosis of co-founder...
23:40 , Aug 14, 2019 |  BC Extra  |  Clinical News

Regeneron data could set up first-in-class approval in lipid-lowering indication

Regeneron's evinacumab could give certain hypercholesterolemia patients a new treatment option, with an FDA submission looming based on new results from a Phase III trial evaluating the first-in-class therapy as an add-on to existing treatments....
21:53 , Aug 14, 2019 |  BC Extra  |  Financial News

Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more

Biotech fares better than markets in sell-off  U.S. biotech indexes fared slightly better than the broader markets Wednesday as stocks tumbled amid fresh signs of a global economic slowdown and a signal from bond markets...
00:18 , Aug 6, 2019 |  BC Extra  |  Clinical News

Next up for GlycoMimetics after tanking in sickle cell disease

Despite plunging 69% to $2.80 on Monday after the Phase III miss of sickle cell disease candidate rivipansel, GlycoMimetics could still turn things around. The small cap has another shot on goal with Phase III...
23:30 , Aug 2, 2019 |  BC Extra  |  Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

Rakuten Medical raises another $100 million  Rakuten Medical Inc. (San Diego, Calif.) raised $100 million in a series C-1 round from existing investor Rakuten Inc. (Tokyo:4755), giving the Japanese internet giant a 22.6% stake. The...
21:28 , Jul 29, 2019 |  BC Extra  |  Financial News

More setbacks for Woodford as suspension extended

Neil Woodford's Woodford Investment Management was dealt a fresh pair of blows on Monday as the firm's flagship Woodford Equity Income Fund had its trading suspension extended until early December, while Woodford's second largest fund...
00:30 , Jul 27, 2019 |  BioCentury  |  Product Development

How Gilead deal positions Galapagos to become Europe’s next big biotech

Galapagos’ pipeline partnership with Gilead sets the company up to become an independent leader of European biotech for years to come, and provides a template that other platform companies could follow. The July 14 deal...
23:34 , Jul 25, 2019 |  BC Extra  |  Financial News

July 25 Financial Quick Takes: Livongo, Castle pop after IPOs; plus a K2HV-Evelo deal, earnings beats for AZ & Roche, and more

Livongo, Castle rise in first trading day  Livongo Health inc. (NASDAQ:LVGO) and Castle Biosciences Inc. (NASDAQ:CSTL) each posted gains in their first day of trading Thursday after pricing upsized IPOs. Digital health play Livongo added...
22:27 , Jul 22, 2019 |  BC Extra  |  Financial News

July 22 Financial Quick Takes: Shanghai's rising STAR; plus Retrotrope and RAPT

Broad gains in debut of Shanghai's STAR market  The first group of 25 companies soared out of the gate on the Shanghai exchange’s science and technology innovation board, posting average gains of 140% in their...
20:36 , Jul 19, 2019 |  BC Extra  |  Financial News

Big discounts likely as auction looms for Woodford assets

While Neil Woodford’s Woodford Investment Management is expected to go ahead with an auction of its private biotech holdings this month, three healthcare investors told BioCentury it isn’t a sure thing the fund will be...